Abstract: An antihypertensive agent containing an effective amount of dipeptide Tyr-Pro and/or a pharmaceutically acceptable salt thereof, the effective amount being from 0.05 to 10 mg/kg body weight/day, and a method for producing the same.
Abstract: Peptides are provided which have improved duration of GnRH antagonistic properties and/or which can be synthesized more economically. These antagonists may be used in the same manner as the compounds of which they are analogs to regulate fertility and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. One particularly effective peptide, a decapeptide analog of the GnRH antagonist Acyline, has the formula: Ac-D-2Nal-D-4Cpa-D-Dpr(methylcarbamoyl)-Ser-4Aph(acetyl)-D-4Aph(acetyl)-Le u-Lys(isopropyl)-Pro-D-Ala-NH.sub.2. It continues to exhibit very substantial suppression of LH secretion at 96 hours following injection. Other economically attractive and pharmacologically effective analogs have the formulas: Ac-D-2Nal-D-4Cpa-Xaa.sub.3 -Ser-4Aph(acetyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2 ; and Ac-D-2Nal-D-4Cpa-Xaa.sub.3 -Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub. 2, wherein Xaa.sub.3 is D-Gln or Gln.
Abstract: Peptides which bind to fibrinogen are disclosed. These peptides have available fibrinogen binding domains having a Trp-Gln-Glu-His-Tyr-Asn, Trp-Gln-Glu-Thr-TyrGln,or Tyr-Glu-Asn-Tyr-Gly-Tyr sequence. Peptides containing at least one of these fibrinogen binding domains are immobilized upon a chromatographic substrate in a preferred embodiment of the invention. This preferred embodiment is useful in an affinity chromatography process to purify fibrinogen.
Type:
Grant
Filed:
January 23, 1998
Date of Patent:
July 21, 1998
Assignee:
Bayer Corporation
Inventors:
Kristine Mondorf, Ruben C. Carbonell, Joseph A. Buettner